| Literature DB >> 32082965 |
María Sanromán Iglesias1, Marek Grzelczak2.
Abstract
The possibility of detecting genetic mutations rapidly in physiological media through liquid biopsy has attracted the attention within the materials science community. The physical properties of nanoparticles combined with robust transduction methods ensure an improved sensitivity and specificity of a given assay and its implementation into point-of-care devices for common use. Covering the last twenty years, this review gives an overview of the state-of-the-art of the research on the use of gold nanoparticles in the development of colorimetric biosensors for the detection of single-nucleotide polymorphism as cancer biomarker. We discuss the main mechanisms of the assays that either are assisted by DNA-based molecular machines or by enzymatic reactions, summarize their performance and provide an outlook towards future developments.Entities:
Keywords: amplification reactions; biomarkers; colorimetric biosensing; gold nanoparticles; plasmonics; single-point mutation
Year: 2020 PMID: 32082965 PMCID: PMC7006498 DOI: 10.3762/bjnano.11.20
Source DB: PubMed Journal: Beilstein J Nanotechnol ISSN: 2190-4286 Impact factor: 3.649
Benefits of liquid biopsy in diagnosis, prediction and prognosis of cancer.
| stage | information/benefits | ref. |
| diagnosis | early detection | [ |
| monitoring of minimal residual disease | [ | |
| prediction | assessment of molecular heterogeneity of overall disease | [ |
| monitoring of tumor dynamics | [ | |
| identification of genetic determinants for targeted therapy | [ | |
| evaluation of early treatment response | [ | |
| assessment of evolution of resistance in real time | [ | |
| prognosis | identification of high risk of recurrence | [ |
| correlation with changes in tumor burden | [ | |
Figure 1Alterations in cell-free DNA. Cell-free DNA can be released from both cancerous and normal cells located in the tumor environment through apoptosis, necrosis or secretion. Once in the bloodstream, cfDNA may exist either free or associated with extracellular entities such as exosomes. cfDNA can carry multiple classes of tumor-derived genetic alterations including point mutations, copy-number fluctuations and structural rearrangements. Reprinted with permission from [45], copyright 2017 Springer Nature.
Figure 2Single-nucleotide polymorphisms (SNPs) are genetic mutations that alter single base in DNA, causing sequence modification in amino acids and malfunction of a corresponding protein. Reprinted with permission from [51], copyright 2014 Elsevier.
Tumor-associated genetic modifications in circulating cell-free DNA.a
| tumor type | tumor-specific aberration |
| colorectal cancer [ | APC, KRAS, PIK3CA, TP53 |
| breast cancer [ | PIK3CA, TP53, BRCA1 |
| ovarian cancer [ | TP53, PTEN, EGFR, BRAF, KRAS |
| pancreatic cancer [ | KRAS |
| non-small-cell lung cancer [ | KRAS |
aKRAS = Kirsten rat sarcoma; APC = adenomatosis polyposis soli; PIK3CA = phosphatidylnositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; TP53 = tumor protein p53, BRCA1 = breast cancer gene 1, PTEN = phosphatase and tensin homolog, EGFR = epidermal growth factor receptor, BRAF = B-Raf proto-oncogene, serine/threonine kinase.
Figure 3Gold nanoparticle-based colorimetric assays in the colloidal phase. a) Cross-linking hybridization assay: Through the specific hybridization of DNA, the distance between the particles decreases leading to a color change. b) Noncross-linking hybridization assay: An increase in the ionic strength causes an aggregation of nanoparticles (blue solution), which is prevented by the presence of the complementary target. c) Colorimetric assay based on unmodified nanoparticles: Single-stranded DNA (ssDNA) stabilizes gold nanoparticles against salt-induced aggregation, while in the presence of double-stranded DNA (dsDNA) particles undergo aggregation.
Summary of particle-based optical assays for the detection of biomarkers.
| nanoparticles (NPs) | target length/biomarker | procedure | limit of detection [Ref.] |
| AuNPs (13 nm) | 30 nt/— | hybridization assay | 10 fmol [ |
| AuNPs (13 nm) | 24 nt/— | colloidal stability of NPS in the presence of ssDNA or dsDNA | 100 fmol [ |
| AuNPs (13 nm) | 24 nt/— | hybridization assay | 10 pmol [ |
| AuNPs (13 nm) | 14 nt/— | salt-induced aggregation of unmodified AuNPs | 0.25 µM [ |
| AuNPs (18 nm) | 20 nt/EGFR | salt-induced aggregation of unmodified AuNPs | 80 µM [ |
| AuNPs (13 nm) | 41 nt/JAK2 | salt-induced aggregation of unmodified AuNPs | 0.2 µM [ |
| AuNPs (13 nm) | 22 nt/— | a logic gate using two distinct target DNA molecules as input to discriminate SNPs using unmodified gold nanoparticles as indicators | 100 pmol [ |
| AuNPs (10 nm) | 34 nt/— | the product of the catalytic strand displacement cascade disassembly AuNPs | 0.1 µM [ |
| AuNPs (13 nm) | 14 nt/— | hybridization assay based on Au@LNA/DNA chimeras | 0.1 µM [ |
| AuNPs (15 nm) | 15 nt/— | noncross-linking hybridization assay | 0.5 µM [ |
| AuNPs (14 nm) | 395 nt/M. tuberculosis | noncross-linking aggregation of Au@DNA within rpoB locus | 30 µg/mL [ |
| AuNPs (14 nm) | 16 nt/— | aggregation of unmodified AuNPs induced by CHA | 0.1 pM [ |
| AuNPs (40 nm), microbeads (MBs, 2.8 μm) | 101 nt/KRAS | MBs@streptavidine hybridizes with the biotinylated target that is complementary to Au@DNA | 20 pM [ |
| AuNPs (13 nm) | 22 nt/— | hybridization of peptide nucleic acid (PNA) and DNA prevents aggregation of nanoparticles | 1 µM [ |
| AuNPs (13 nm) | 24 nt/CFTR | hybridization assay using a miniaturized optical monitoring system | 10 nM [ |
| AuNPs (15 nm) | 22 nt/— | sequential hybridization to the target by allele-specific surface-immobilized capture probes and gene-specific Au@DNA | 500 ng genomic DNA [ |
| AuNPs (15 nm) | 24 nt/— | hairpin-based amplification assay combined with lateral flow test | 10 pM [ |
| AuNPs (13, 20, 40 nm) | 24 nt/— | aggregation of AuNPs by target-induced DNA circuits | 200 pM (HCR), 14 pM (CHA) [ |
| AuNPs (30 nm), MBs (2–3 μm) | 27 nt/— | MBs@DNA, Au@DNA and target hybridization followed by magnetic separation and scanometric detection based on silver reduction for signal amplification | 500 zM (10 copies) [ |
| AuNPs (13 nm) | 27 nt/— | sandwich assay between target, Au@DNA and a flatbed scanner; signal amplification by Ag reduction | 50 fM [ |
| AuNPs (20 nm) | 84 nt/EGFR | hairpin assembly produces short DNA catalyst, which induces aggregation of unmodified AuNPs | 7.7 fM [ |
| AuNRs | 24 nt/— | combination of HCR and unmodified gold nanorods for signal transduction | 1.47 nM [ |
| AuNPs (13 nm) | 19 nt/BRCA1 | DNA-fueled molecular machine modulates the kinetics of Au@DNA aggregation | 0.26 nM [ |
| AuNPs (15 nm) | 38 nt/— | target DNA hybridizes with Au@DNA, triggering a HCR that inhibits aggregation of AuNPs | 0.5 nM [ |
| AuNPs (43 nm) | 22 nt/— | oriented aggregation of nanoparticles on Y-shaped DNA duplex | 10 pM [ |
| AuNPs (40 nm), MBs (1.5 μm) | 30 nt/— | MBs@DNA, Au@DNA, target hybridization followed by magnetic separation and scanometric detection based on silver reduction for signal amplification | 100 amol [ |
| AuNPs (15 nm) | 265 nt/hepatitis C | release and adsorption of free primers on the nanoparticle ensuring stability | 50 copies [ |
| AuNPs (75 nm) | 22 nt/— | hybridization assay | 3 nM [ |
| AuNPs (5, 10, 12, 20 nm) | 60 nt/KRAS | target-stabilized nanoparticles interacting with matching or mismatching probe lines in a microfluidic channel | 5 fmol [ |
| AuNPs (13 nm), growth (40 nm) | 20 nt/— | DNA hybridization-mediated autocatalytic overgrowth of gold nanoparticles | 60 nM [ |
| AgNPs (13 nm) | 22 nt/— | PNAs induce aggregation of citrate-stabilized AuNPs, which is prevented by DNA targets that complex selectively to PNA | 1 µM [ |
| AuNPs (18 nm) | 12, 21, 42 nt/c-KIT | selective aggregation of PNA-stabilized AuNPs by target DNA and positively charged AuNPs through electrostatic interactions | 0.1 µM [ |
| AuNPs (15 nm) | 30 nt/hepatitis A | combination of “click chemical” ligation chain reactions on gold nanoparticles and a magnetic separation to detect DNA and RNA | 50 zM [ |
| AuNPs (13, 46, 63 nm) | 19 nt/BRCA1 | colorimetric detection based on sandwich assay | 10.85 fmol [ |
| AuNPs (63 nm) | 70, 140 nt/EGFR | colorimetric detection based on sandwich assay combined with a preincubation step | 100 pM [ |
| AuNPs (25, 53 nm) | 70, 140 nt/EGFR | chemical modifications of capture probes for a selective aggregation of nanoparticles | 5 nM [ |
| SiO2 microparticles (MPs) and AuNPs | 22 nt/miR-21 | DNA I located on SiO2MPs captures miRNA, DNA II labeled with EDTA·2Na chelates Au3+ ions and regulates the growth of AuNPs | 8.9 fM [ |
| AuNPs (56, 13 nm) | 30 nt/— | modulation of the enzyme activity of thrombin on the surface of AuNPs relative to fibrinogen | 12 pM [ |
| AuNPs (13 nm) | 112, 230, 316 nt/BRCA1 | allele‐specific PCR with thiol-labeled primers for the specific stabilization of unmodified AuNPs | 20 ng genomic DNA [ |
| AuNPs (13 nm) | 40 nt/KRAS | selective ligation of two adjacent Au@DNA probes in the presence of a mutation | 74 pM [ |
| AuNPs (14 nm) | 36, 48, 80 nt/— | nanoparticle amplification assisted by nicking endonuclease (NEase) for the detection of target DNA | 10 pM [ |
| AuNPs (15 nm) | 24 nt/keratin 10 | isothermal strand displacement polymerase reaction to produce biotin–digoxin-labeled dsDNA in combination with a lateral flow strip | 0.08 pM [ |
| AuNPs (20 nm) | 40 nt/— | aggregation of Au@DNA in the presence of single-strand-specific nuclease | 100 nM [ |
| AuNPs (13 nm) | 22 nt/miR-122 | miRNA–probe heteroduplex as substrate of double strand nuclease, releasing a probe to aggregate the nanoparticles | 16 pM [ |
| AuNPs (13 nm) | 43 nt/EGFR | coupling of invasive reactions with NEase-assisted nanoparticle amplification to produce linkers that prevent aggregation | 1 pM [ |
| AuNPs (12 nm) | 33 nt/— | exonuclease III (Exo III)-induced cleavage of dangling ends on Au@dsDNA causing specific aggregation | 2 nM [ |
| AuNPs (13 nm) | 23 nt/— | coupling of polymerase and NEase through an isothermal exponential amplification reaction to selectively detach DNA from Au@DNA | 46 fM [ |
| AuNPs (13 nm) | 30 nt/KRAS | cyclic enzymatic cleavage based on Exo III in the presence of the target and a linker to induce aggregation of Au@DNA | 15 pM [ |
| AuNPs (15 nm), MBs (1 μm) | 46 nt/BRCA1 | Au@DNA complexed with magnetic beads using horseradish peroxidase (HRP, enzymatic catalysis) and bovine serum albumin (BSA, nonspecific blocker) | 25 pM [ |
| AuNPs (13 nm) | 34 nt/— | combination of padlock probe for rolling-circle amplification and NEase-assisted nanoparticle amplification | 1 pM [ |
| AuNPs (42 nm) | 1130 nt/ chlamydia trachomatis | isothermal target and probe amplification for the hybridization of target amplicons and Au@DNA followed by RNA cleavage | 102 copies [ |
| AuNPs (15 nm) | 16, 32 nt/ cytochromes P450 | single‐base primer extension in combination with noncrosslinking assay | 1 μM [ |
| AuNPs (13 nm) | 16–80 nt/rtM204V | selective stabilization of unmodified AuNPs with nucleoside monophosphates after nuclease cleavage | 5 nM [ |
| AuNPs (20 nm) | —/hepatitis B | ligation chain reaction to induce aggregation of Au@DNA | 20 aM [ |
| AuNPs (13 nm) | 26 nt/— | combination of AuNP fluorescence anisotropy and toehold-mediated strand-displacement reaction | 0.95 nM [ |
| PS NPs (40 nm) | 57 nt/PKD1 | fluorescence-enhancement from nanoparticle-hybridized DNA complexes by nanostructured photonic crystals due to phase matching of excitation and emission | 50 aM [ |
| Ag nanoclusters | 22 nt/miR-141 | target-triggered CHA and fluorescence enhancement of DNA–silver nanoclusters to detect miRNA | 0.3 nM [ |
| AuNPs (5 nm) | 24 nt/— | distance-dependent modulation of electrochemiluminescence from CdS:Mn nanocrystals by gold nanoparticles. | 2.9 fM [ |
| quantum dots (QDs, 10 nm) | 19 nt/miR-21 | p19-QDs with multiplex antenna capture miRNA-21/antimiRNA-21-Cy3 duplex to form a Förster resonance energy transfer (FRET) detection system between QDs and Cy3 | 0.6 fM [ |
| MBs (1 μm) | 21 nt/miR-27a | dual toehold-mediated circular strand displacement amplification-based DNA circuit as fluorescent strategy for the detection of miRNA-27a | 0.8 pM [ |
| AuNPs (5 nm) | 25 nt/— | enhancement of the electrochemiluminescence of a CdS film by a combination of an isothermal circular amplification reaction of polymerase, NEase and Au@DNA | 5 aM [ |
| QDs (15 nm) | 21 nt/miR-196a2T | miRNA detection by coupling rolling circle amplification and NEase with streptavidin-coated QDs | 51 aM [ |
| carbon dots (CDs, 8 nm) | 52 nt/H7N9 virus | carbon nanodot‐based fluorescent sensing strategy for H7N9 utilizing isothermal strand displacement amplification | 3.4 fM [ |
| graphene QDs (5 nm) | 22 nt/miR-141 | pentaethylenehexamine- and histidine-functionalized graphene QD for a microRNA fluorescence biosensing nanoplatform coupled with molecular beacon double-cycle amplification | 0.43 aM [ |
| QDs (5 nm) | —/miR-148, miR-21 | QD-assisted FRET signal generation | 42 fM [ |
| AuNPs (5 nm) | 22 nt/LET7 | differential interference contrast microscopy with a microarray platform comprising hairpins as capture probes and Au@DNA as signaling probe | 10 fM [ |
| AuNPs (40 nm) | 45 nt/p53 | aggregation of oligonucleotide-modified organic nanospheres coded with fluorescent dyes (red/green/blue) | 200 fmol [ |
| AuNPs (15 nm) | 15 nt/— | surface plasmon resonance imaging of Au@DNA in a PDMS–gold–glass hybrid microchip | 32 nM [ |
| AuNPs (50 nm) | 28, 60, 90 nt/— | dark-field microscopy for the detection of head-to-tail Au@DNA hybridization | 4 pM (28 nt)/40 pM (60 nt) [ |
| AuNPs (50 nm) | 46 nt/HeLa cells | dark-field microscopy combined with Rayleigh scattering spectrophotometry for single-particle detection | 10 HeLa cells [ |
Figure 4Discrimination of SNPs by means of the kinetics of particle aggregation. a) The spurious catalyst decelerates the toehold-exchange reaction and thus the formation of aggregates. (b) Time-dependent change of the color of the assay using spurious and correct targets. Reprinted with permission from [83], copyright 2014 John Wiley and Sons.
Figure 5Working principle of the colorimetric assay for the detection of EGFR mutants in long DNA sequences. The presence of a target releases the catalyst oligonucleotide initiating CHA, which in turn progressively aggregate gold nanoparticles. Reprinted with permission from [81], copyright 2018 John Wiley and Sons.
Figure 6The combination of unmodified gold nanorods as signal transducers in an HCR amplification process for the colorimetric detection of single-base mutations. Reprinted with permission from [82], copyright 2018 Elsevier.
Figure 7Working principle of EASA for the colorimetric detection of DNA mismatches. The consumption of a large amount of linker DNA strands by a few initial target molecules leads to the preservation of the colloidal stability of gold nanoparticles. In the absence of a target, the intact linker DNA hybridizes with Au@DNA leading to a gradual color change. Reprinted with permission from [108], copyright 2011 Elsevier.
Figure 8Schematic illustration of the colorimetric method for the detection of specific miRNA based on the amplification of DSN-assisted nanoparticles using AuNPs as the signal output. Reprinted with permission from [104], copyright 2015 Royal Society of Chemistry.
Figure 9Colorimetric method for the detection of specific miRNA based on the combination of enzyme-assisted exponential amplification and AuNP-based colorimetric detection. The sensing probe attached to the gold nanoparticles can be easily disrupted by the enzymes, ensuring thus an improved performance. Reprinted with permission from [107], copyright 2016 Elsevier.
Figure 10The combination of isothermal strand-displacement polymerase reactions and lateral flow strip for visual detection of gene mutations. a) Schematic illustration of isothermal strand-displacement polymerase reactions and the formation of digoxin- and biotin- attached duplex DNA complexes b) The mechanism of detection on lateral flow strip and c) visualization of the presence of mutation. Reprinted with permission from [102], copyright 2012 Elsevier.
Figure 11The use of gold nanoparticles as fluorescence quencher in the discrimination of SNP through cyclic enzyme-aided polymerization and nicking of oligonucleotides. The presence of a mutation decreases the fluorescence of the CdS films by nearly 90%. Reprinted with permission from [121], copyright 2011 Royal Society of Chemistry.
Figure 12Colorimetric DNA detection through rolling circle amplification (RCA) and NEase-assisted nanoparticle amplification (NEANA). a) Working principle of the assay. b) Colorimetric detection of single-point mutation located in the proximity of ligation point. Reprinted with permission from [110], copyright 2012 John Wiley and Sons.
Figure 13a) The working principle of DNA target detection through an invasive reaction coupled with NEase-assisted nanoparticle amplification. b) Optical characterization of the assay solution spiked with different amounts of c.2573 T>G mutant EGFR gene in the presence of a background wild-type EGFR sequence, showing a specificity down to 1%. c) The relation of increased absorbance with increasing the relative concentration of mutated sequence in assay mixture. Reprinted with permission from [105], copyright 2015 Elsevier.